PO-506 The dynamics of HER2 status in esophageal adenocarcinoma
Sign Up to like & getrecommendations! Published in 2018 at "ESMO Open"
DOI: 10.1136/esmoopen-2018-eacr25.1007
Abstract: Introduction Trastuzumab, a monoclonal antibody against HER2, has become standard of care for metastatic HER2-overexpressing esophagogastric adenocarcinoma and is currently investigated as (neo)adjuvant treatment option in HER2-positive esophagogastric adenocarcinoma. The HER2 status is commonly determined… read more here.
Keywords: status; discordance; her2 status; treatment ... See more keywords